Cytek Biosciences Raises Full-Year Outlook Despite Slight Q2 Revenue Miss
CTKB sits 28% above its 52-week low of $3.28.
Summary
Cytek Biosciences reported Q2 revenue of $48.14 million, a slight miss against estimates of $48.61 million, and a wider net loss of $12.16 million. This follows the 8-K filed earlier today. Despite the Q2 miss, the company raised its full-year 2026 revenue outlook midpoint by $1 million to a range of $207 million to $212 million. The upward revision in guidance is a significant positive that could outweigh the historical revenue miss for investors.
At the time of this announcement, CTKB was trading at $4.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $539.8M. The 52-week trading range was $3.28 to $6.18. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.